BATON ROUGE, La (BRPROUD)- Skymount Medical, a drug discovery company and Louisiana State University (LSU) announced that human studies are underway on its unique combination of therapies, known as SM-19, for COVID-19 patients.
The therapeutics were discovered using an artificial intelligence (AI) platform that reduces the time to drug discovery. The AI predicted up to 97 percent efficacy. The medications being investigated are already FDA approved for other conditions, which will accelerate the time for SM-19 to become widely available.
At this time, there are no approved oral medications to reduce COVID-19 symptoms in people who are not hospitalized. The SM-19 treatment was designed to be effective against several COVID-19 variants, decreases viral load, and reduces the duration of symptoms. The approach is to treat adult patients at the first sign of infection to avoid hospitalization and eliminate ICU visits. The compassionate use studies began yesterday in Europe and are expected to continue throughout the United States, the United Kingdom, India and Brazil.
Skymount Medical and LSU are working in partnership on COVID-19 treatments discovered using AI. DeepDrug™️ is an AI platform that identifies and develops novel therapeutics. It was created by an interdisciplinary team of Louisiana State University researchers led by Dr. Supratik Mukhopadhyay, co-inventor and associate professor in the LSU Department of Computer Science. The world-leading AI platform was a semi-finalist in the IBM Watson AI X-Prize, a $5 million award for using AI to tackle global challenges.